Sunshine Biopharma Inc. Earnings Per Share Disclosure
The following table* sets forth the computation of basic net income (loss) per share:
| Year Ended December 31, | 2025 | 2024 | ||||||
| Net gain (loss) attributable to common stock | $ | (5,975,352 | ) | $ | (5,134,116 | ) | ||
| Weighted average outstanding shares of common stock (Basic) | ||||||||
| Net gain (loss) per share attributable to common stock (Basic) | $ | ) | $ | ) | ||||
* Diluted net gain (loss) per share is not included in this table as the Company incurred net losses for the years ended December 31, 2025 and 2024 and inclusion of dilutive instruments would have an anti-dilutive effect.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Apr 3, 2026 | Showing above |
| 2024 | Apr 1, 2025 | |
| 2023 | Mar 28, 2024 | |
| 2022 | Apr 4, 2023 | |
| 2021 | Mar 21, 2022 | |
| 2020 | Mar 30, 2021 | |
| 2019 | May 1, 2020 | |
| 2018 | Apr 12, 2019 | |
| 2017 | Apr 2, 2018 | |
| 2016 | Apr 17, 2017 | |
| 2015 | Mar 25, 2016 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.